We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

We recently compiled a list of the 12 Best Big Name Stocks to Invest in Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best big name ...

Ozempic, Novo Nordisk’s semaglutide-based diabetes treatment ... They were joined by RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and Lyfe Capital.

or who have Type 2 diabetes. Those rumors reached such a fever pitch last year that Lilly took it upon itself to produce a pair of commercials calling out that off-label use. One of the ads seemed ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

For the past year, Jonsson has run Lilly Diabetes and Obesity, which means he oversees everything from insulin shots to the newer, high-demand drugs now known as "weight-loss" shots: Mounjaro ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on Feb.

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...